Lexeo Therapeutics (LXEO) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company overview and pipeline focus

• Focuses on genetic medicines for cardiovascular diseases, with lead programs in Friedreich's ataxia (FA) and PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM).

• FA program targets cardiac pathology and shows neurologic improvement; PKP2-ACM program has completed phase I enrollment with data expected later this year.

• Additional early-stage cardiovascular programs are in development.

Clinical strategy and trial design for FA

• Disease education efforts leverage societies, social media, and advocacy groups to raise awareness of cardiac involvement in FA.

• LVMi is used as a precise, objective cardiac endpoint, with changes linked to mortality risk.

• Troponin elevation is considered an early marker for cardiac involvement and potential treatment trigger.

• Phase I/II data show normalization of LVMi and reduction in troponin, with neurologic improvements on the mFARS scale.

• Registrational trial uses the same LVMi criteria as earlier studies and is powered to detect a 15% effect size, exceeding the 10% clinical bar.

Commercial and operational planning

• Education and medical affairs teams are expanding to increase clinician awareness and trial recruitment.

• Commercial strategy focuses on market access, payer engagement, and pricing based on comprehensive data.

• Concentration of patients at specialized centers allows for a lean commercial infrastructure.